Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort study.
Ravera F, Borea R, Cirmena G, Dameri M, Ferrando L, Gallo M, Casini C, Fallani N, Stabile M, Barbero V, Murialdo R, Tixi L, Cappuccio M, Cuboni A, Sivieri I, Fornarini G, De Maria A, Ballestrero A, Zoppoli G. Ravera F, et al. Among authors: dameri m. J Transl Med. 2022 May 14;20(1):230. doi: 10.1186/s12967-022-03429-0. J Transl Med. 2022. PMID: 35568887 Free PMC article.
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.
Cirmena G, Ferrando L, Ravera F, Garuti A, Dameri M, Gallo M, Barbero V, Ferrando F, Del Mastro L, Garlaschi A, Friedman D, Fregatti P, Ballestrero A, Zoppoli G. Cirmena G, et al. Among authors: dameri m. JCO Precis Oncol. 2022 Feb;6:e2100198. doi: 10.1200/PO.21.00198. JCO Precis Oncol. 2022. PMID: 35201850 Free PMC article.
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Ferrando L, Vingiani A, Garuti A, Vernieri C, Belfiore A, Agnelli L, Dagrada G, Ivanoiu D, Bonizzi G, Munzone E, Lippolis L, Dameri M, Ravera F, Colleoni M, Viale G, Magnani L, Ballestrero A, Zoppoli G, Pruneri G. Ferrando L, et al. Among authors: dameri m. PLoS Genet. 2023 Jan 3;19(1):e1010563. doi: 10.1371/journal.pgen.1010563. eCollection 2023 Jan. PLoS Genet. 2023. PMID: 36595552 Free PMC article.
Standard Operating Procedures (SOPs) for non-invasive multiple biomarkers detection in an academic setting: A critical review of the literature for the RENOVATE study protocol.
Dameri M, Cirmena G, Ravera F, Ferrando L, Cuccarolo P, Stabile M, Fanelli GN, Nuzzo PV, Calabrese M, Tagliafico A, Ballestrero A, Zoppoli G. Dameri M, et al. Crit Rev Oncol Hematol. 2023 May;185:103963. doi: 10.1016/j.critrevonc.2023.103963. Epub 2023 Mar 15. Crit Rev Oncol Hematol. 2023. PMID: 36931614 Free article. Review.
JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib.
Ceccardi A, Dameri M, Ravera F, Gilardi N, Stabile M, Lombardo I, Ceresa D, Colombo M, Vigo T, Cigolini B, Rivoli G, Dragani M, Solimano I, Garuti A, Bellodi A, Ballestrero A, Ferrando L, Zoppoli G. Ceccardi A, et al. Among authors: dameri m. Br J Haematol. 2025 Feb;206(2):758-762. doi: 10.1111/bjh.19979. Epub 2025 Jan 15. Br J Haematol. 2025. PMID: 39814683 Free PMC article. No abstract available.
62 results